Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sildenafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 19/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 3/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 3/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | PDE2A | O00408 | 1/20 | 1.00 |
| ▸ | ABCC5 | O15440 | 1/20 | 1.00 |
| ▸ | PDE6D | O43924 | 1/20 | 1.00 |
| ▸ | PDE8A | O60658 | 1/20 | 1.00 |
| ▸ | PDE9A | O76083 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | PDE6A | P16499 | 1/20 | 1.00 |
| ▸ | PDE6G | P18545 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PDE6B | P35913 | 1/20 | 1.00 |
| ▸ | PDE6C | P51160 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sildenafil SCHEMBL1895 | 1.00 | PDE5A (1.00) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL29361663 | 1.00 | PDE5A (1.00) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL584340 | 0.99 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL1801562 | 0.99 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL19410952 | 0.99 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL5691322 | 0.99 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL7915871 | 0.99 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL6689399 | 0.99 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL20544481 | 0.98 | PDE5A (0.97) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL3399278 | 0.98 | PDE5A (0.95) | PDE5APDE3BPDE3AABCC4PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180941-A1 | 3-(1-[3-(1,3-Benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoic acid derivatives as NEP inhibitors | PFIZER INC | 2004-09-16 | — | — | US | claimed |
| WO-2023205369-A1 | COMBINATORIAL PHARMACOTHERAPY FOR THE RESTORATION OF NEURO-FUNCTION AND COMBINATORIAL PHARMACOLOGICAL COMPOSITION THEREFORE | NEURO-INNOVATORS, LLC. (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-3137065-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | Pharnext (FR) | 2017-03-08 | — | — | EP | disclosed |
| WO-2015165948-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | PHARNEXT (FR) | 2015-11-05 | — | — | WO | disclosed |
| EP-1623026-A1 | CRYSTAL OF PDE5, ITS CRYSTAL STRUCTURE AND ITS USE IN DRUG DESIGN | Pfizer Limited (GB) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004097010-A1 | CRYSTAL OF PDE5, ITS CRYSTAL STRUCTURE AND ITS USE IN DRUG DESIGN | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| EP-1468082-A1 | CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 5 AND USE THEREOF | Pfizer Limited (GB) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003038080-A1 | CRYSTAL STRUCTURE OF PHOSPHODIESTERASE 5 AND USE THEREOF | PFIZER LIMITED (GB) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180941-A1 | 3-(1-[3-(1,3-Benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoic acid derivatives as NEP inhibitors | MME, PREP, DNPEP | PDE5A 451/4885PDE3B 400/4885PDE3A 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.